-
New programme increases use of HIV medication in injection-drug users
europeanpharmaceuticalreview
April 22, 2019
Researchers have outlined a simple method to increase the number of injection-drug taking individuals with HIV to adhere to their medication…
-
Regular infusions of a novel antibody may suppress HIV for four months
europeanpharmaceuticalreview
April 19, 2019
Regular infusions of a novel antibody may suppress HIV for four months.
-
Weekly Infusion May Be Effective, Easier HIV Therapy
drugs
April 18, 2019
The advent of highly active antiretroviral therapy (HAART) in the 1990s revolutionized HIV/AIDS treatment.
-
FDA Approves Dovato (dolutegravir/lamivudine) for HIV-1 Infection
drugs
April 17, 2019
FDA Approves Dovato (dolutegravir/lamivudine) for HIV-1 Infection.
-
ViiV’s two-drug regimen Dovato gets FDA approval for HIV-1
pharmaceutical-technology
April 11, 2019
ViiV’s two-drug regimen Dovato gets FDA approval for HIV-1.
-
FDA Approves Two-Drug HIV Therapy for Previously Untreated Patients
americanpharmaceuticalreview
April 11, 2019
FDA Approves Two-Drug HIV Therapy for Previously Untreated Patients.
-
GSK’s HIV drug Dovato gets FDA approval
pharmatimes
April 10, 2019
The U.S. Food and Drug Administration (FDA) has announced the approval of the first two-drug complete regimen for HIV-infected patients who have never received antiretroviral treatment.
-
FDA clears GSK's Dovato, first 2-drug regimen for new HIV adults
fiercepharma
April 10, 2019
In a landmark win for GlaxoSmithKline’s ViiV Healthcare and its ambition to reduce the number of medications HIV patients are taking—and...
-
FDA Approves First Single-Tablet, Two-Drug Treatment for Untreated HIV
drugs
April 10, 2019
FDA Approves First Single-Tablet, Two-Drug Treatment for Untreated HIV
-
ViiV announces long-term positive results for Juluca combination
pharmaceutical-technology
April 09, 2019
London-based ViiV Healthcare has announced three-year results from its Sword-1 and Sword-2 trials.